Pancreatic Adenocarcinoma
Course AuthorsParvin Peddi, M.D., and Andrea Wang-Gillam, M.D. Dr. Peddi is a hematology/oncology fellow and Dr. Wang-Gillam is an Assistant Professor, Washington University School of Medicine, St. Louis, MO Within the past 12 months, Dr. Peddi and Dr. Wang-Gillam report no commercial conflict of interest. Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose. Estimated course time: 1 hour(s). Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
 
Epidemiology and Risk Factors Although the 10th most common cause of cancer in the United States, pancreatic cancer continues to far outpace its incidence rate with respect to mortality. In 2011, an estimated 37,660 patients died of pancreatic cancer, making it the fourth most common cause of cancer death in men and women. The incidence and mortality rates have unfortunately remained almost unchanged for the past several decades. The majority of these tumors (85%) are adenocarcinomas arising from the ductal epithelium. In this presentation we will only focus on pancreatic adenocarcinoma. The following factors have been associated with increased risk of pancreatic adenocarcinoma:
Males and females have essentially equal incidence. African Americans have a higher incidence than white Americans. Approximately 90% of pancreatic adenocarcinoma is sporadic, while 10% is familial. Genes most commonly associated with familial cases of pancreatic adenocarcinoma are BRCA-1, BRCA-2, and CDKN2A/p16. Molecular Pathogenesis Multiple genetic mutations have been found in patients with pancreatic adenocarcinoma. KRAS is one of the most commonly mutated genes in pancreatic adenocarcinoma, occurring sporadically in more than 90% of tumors.(1) This is an activating mutation and appears to happen early in the pathogenesis of pancreatic cancer as it is also found in non-invasive precursors such as intraductal papillary mucinous neoplasms. Pancreatic cancer is typically diagnosed late in the course of disease... Loss of function of tumor suppressor genes is also frequently found. The most common lost gene is the p16/CDKN2A gene on chromosome 9p, which is somatically inactivated in almost all pancreatic cancers.(2) The loss of CDKN2A can be somatic or as part of the familial atypical mole melanoma syndrome (FAMM) in which patients are at increased risk of both pancreatic cancer and melanoma. Other less common mutations are TP53, SMAD4, and BRCA, especially BRCA-2. Clinical Manifestations and Diagnosis Initial workup usually includes CAT scan (CT) or right upper quadrant (RUQ) ultrasound if the patient is presenting with new onset jaundice. Diagnosis requires tissue biopsy typically obtained by endoscopic retrograde cholangiopancreatography (ERCP) or by an endoscopic ultrasound (EUS)-guided biopsy. ERCP can be both diagnostic and therapeutic when employed to place stents for relieving pressure in the biliary duct. EUS, as explained below, can also be therapeutic if used for celiac plexus neurolysis and pain control. There has been great interest in the use of serum tumor markers for the diagnosis of pancreatic cancer. CA 19-9, a sialylated Lewis (a) blood group antigen, is commonly expressed and shed in hepatobiliary or hepatic cancers, and is the most tested marker in the setting of pancreatic cancer. CA 19-9 is not, however, tumor specific or 100% sensitive.(3) It can be elevated in benign conditions such as pancreatitis or biliary obstruction from other causes such as cholelithiasis. It can also be falsely negative in individuals who are negative for Lewis antigens. Therefore, CA 19-9 is not used to make the diagnosis of pancreatic cancer. CEA, carcinoembryonic antigen, is also sometimes elevated in patients with pancreatic cancer but is more commonly utilized for colorectal cancer, as it is not as sensitive or specific for pancreatic cancer. Surgical resection is currently the only possibly curative technique for pancreatic cancer. Staging Treatment - Surgical Resection The most common procedure performed is the Whipple, which involves resection of the pancreatic head in addition to the first and second portions of the duodenum, the common bile duct and the gallbladder. The distal portion of the stomach is also removed in the “classic” Whipple. The following YouTube video provides an explanation of the procedure: (http://www.youtube.com/watch?v=x4NJTNLq3xw). A different surgery is needed for pancreatic cancers in the pancreatic body or tail, which involves distal pancreatectomy, often concurrent with splenectomy, for complete dissection of lymph nodes present along the course of the splenic arteries. Role for Adjuvant Therapy Given similar modest improvements seen in other trials, the NCCN (National Comprehensive Cancer Network) currently endorses the use of adjuvant chemotherapy with either gemcitabine or 5-FU/leucovorin, although gemcitabine is preferred because of its favorable toxicity profile. Concurrent chemotherapy and radiation are also accepted and commonly practiced in the United States.(6) At present, adjuvant studies comparing chemotherapy only versus chemotherapy combined with radiation are ongoing. Role for Neoadjuvant Therapy Neoadjuvant therapy in the setting of borderline resectable disease makes the most sense. Most studies of neoadjuvant therapy have been retrospective, while the few prospective studies show improved completion rate of chemotherapy and decreased rates of surgery due to presence of more advanced disease on subsequent imaging. No survival benefit, however, has been demonstrated in neoadjuvant therapy versus adjuvant therapy. Currently, researchers are recruiting for a phase III study that compares adjuvant therapy to a combination of neoadjuvant and adjuvant therapy in resectable disease. This trial should help answer the question of the role of neoadjuvant therapy in resectable pancreatic cancer (http://clinicaltrials.gov/ct2/show/NCT01314027?term=NCT01314027&rank=1). Neoadjuvant therapy in the setting of borderline resectable disease makes the most sense, as it would potentially render a borderline case resectable. No prospective phase III trials have addressed this scenario, however. The current approach varies by institution but it appears that most physicians prefer neoadjuvant therapy as opposed to immediate surgery. Fortunately, there are several ongoing trials assessing R0 resection rate following neoadjuvant chemotherapy in patients with borderline resectable disease to establish the possible benefits of this approach (for example, Clinicaltrials.gov NCT01359007, using FOLFIRINOX chemotherapy). Systemic Treatment for Locally Advanced and Metastatic Disease Until recently, gemcitabine and the less commonly used combination with erlotinib were the only regimens for unresectable pancreatic cancer. In May of 2011, a French group published the results of the randomized phase III PRODIGE trial that showed dramatic improvement in both median progression-free survival (6.4 months vs. 3.3 months) and median overall survival (11.1 months vs. 6.8 months) in favor of the group receiving FOLFIRNOX vs. the group receiving gemcitabine.(9) FOLFIRINOX is a biweekly regimen consisting of 5-FU/leucovorin, irinotecan and oxaliplatin. It is more toxic than gemcitabine, however, with high rates of neutropenia and diarrhea among other side effects. Therefore, only patients with high performance status should be offered this regimen. Somewhat unique to pancreatic cancer is the requirement for substantial palliative procedures. Chemoradiation for Locally Advanced Disease Palliation of Locally Advanced and Metastatic Disease Biliary or Gastric Obstruction Sometimes a biliary stent cannot be placed as a result of ERCP failure due to the mass obstructing the gastric outlet. In this situation, percutaneous biliary drainage is often needed. An open biliary-enteric bypass can also be performed, usually if patients are undergoing surgery for resection but found to have unresectable disease during the operation. Symptomatic gastric outlet obstruction also occurs in 10-25% of patients. Similar to biliary stents, an enteral stent can relieve the obstruction. Another alternative for a fit patient with a life expectancy of 3-6 months is duodenal bypass surgery with or without a jejunostomy tube.(12) Cancer-Associated Pain Pancreatic Insufficiency Thromboembolic Disease Other Symptoms Summary Pancreatic cancer continues to be one of the most lethal cancers in the twenty-first century despite recent advances. Surgery remains the only chance at cure but most completely resected patients still die of their disease. Adjuvant therapies are usually used to improve the results of surgery alone. Systemic chemotherapy with gemcitabine and more recently, FOLFIRINOX, are recommended when resection is not an option. Until more effective therapies are found, managing symptoms such as pain and biliary obstruction are key elements in the management of patients with pancreatic cancer. Suggested Reading |